We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Microplastics, Nanoplastics and the Heart: Emerging Human Data Link Environmental Particles to Cardiovascular Risk

MedXY Editorial Team•Oct 2, 2025•Cardiology
cardiovascular diseaseinflammationmicroplasticsnanoplastics

Highlight

– Multiple prospective human studies report detectable microplastics and nanoplastics (MNPs) in coronary blood, cardiopulmonary-bypass (CPB)–exposed blood, and carotid atheromas.
– MNP presence correlates with local and systemic inflammatory markers and with higher risk of major adverse cardiovascular events (MACE) in observational cohorts.
– Findings are biologically plausible given preclinical evidence but are subject to potential contamination, methodological heterogeneity, and residual confounding; causality remains unproven.

Study background and disease burden

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Subclinical Liver Disease as a Silent Driver of Cardiovascular Risk: Insights from a Large-Scale Prospective StudySubclinical liver disease, marked by steatosis, fibrosis, and functional impairment, independently and synergistically increases cardiovascular disease risk. Incorporating non-invasive liver biomarkers could enhance CVD risk prediction andSep 15, 2026Unveiling the Cardiovascular Toll of Long-Term Wildfire Smoke PM2.5 Exposure in Older AmericansLong-term cumulative exposure to wildfire smoke PM2.5 significantly increases cardiovascular hospitalizations among U.S. older adults, with notable risks in ischemic heart disease and arrhythmias, highlighting the need for targeted public hSep 15, 2026Designing Cardiovascular Outcomes Trials in Clonal Hematopoiesis: A Precision Medicine ImperativeClonal hematopoiesis of indeterminate potential (CHIP) poses a novel cardiovascular risk. This article explores challenges and strategies for designing cardiovascular outcomes trials tailored to CHIP’s genetic heterogeneity and clinical comSep 15, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Impact of Germline and Somatic DNMT3A Variants on Pulmonary Arterial Hypertension: A New Frontier in Biomarkers and Therapeutics
Germline and somatic variants in DNMT3A and other CHIP genes elevate pulmonary arterial hypertension risk, including connective tissue disease-associated forms, through pro-inflammatory pathways, highlighting novel biomarkers and therapeuti
Sep 8, 2026
Rising Cardiovascular Disease Burden at Cancer Diagnosis: Insights from a National English Cohort and Future ProjectionsThis national English study reveals a significant increase in pre-existing cardiovascular disease among patients at cancer diagnosis over two decades, projecting nearly half will have cardiovascular comorbidities by 2050, underlining urgentSep 3, 2026
Sustained Cardiovascular Benefits of Intensive Blood Pressure Management Led by Nonphysician Providers: 7-Year Follow-Up of the CRHCP TrialLong-term intensive BP control led by trained nonphysician community providers significantly lowers cardiovascular risk over 7 years, with benefits persisting 3 years post-intervention in rural China.Aug 29, 2026